AIMS: Tamoxifen is metabolized by cytochrome P450s, with an important role for CYP2D6. Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancer patients using tamoxifen. Here, we aimed to confirm this in a large group of 499 patients. MATERIALS & METHODS: A total of 499 estrogen receptor-positive primary breast tumor specimens of advanced disease patients treated with first-line tamoxifen were genotyped for CYP2C19*2 and *17 variant alleles, with primary end point time-to-treatment failure (TTF). Effects of CYP2C19, independent of treatment, were analyzed in 243 primary systematic untreated patients. RESULTS: CYP2C19*2 hetero- and homozygote patients combined showed significantly longer TTFs (hazard ratio [HR]: 0.72; 95% CI: 0.57-0.90; p = 0.004). In multivariate analysis, including CYP2D6*4 status, CYP2C19*2 remained independently associated with TTF (HR: 0.73; 95% CI: 0.58-0.91; p = 0.007). In untreated patients, the CYP2C19*17 allele was significantly associated with a longer disease-free interval (HR: 0.66; 95%CI: 0.46-0.95; p = 0.025). CONCLUSION: CYP2C19 genotyping is potentially important for tamoxifen therapy for advanced disease and for breast cancer prognosis.
AIMS: Tamoxifen is metabolized by cytochrome P450s, with an important role for CYP2D6. Recently, we demonstrated in 80 patients that CYP2C19*2 is associated with increased survival in breast cancerpatients using tamoxifen. Here, we aimed to confirm this in a large group of 499 patients. MATERIALS & METHODS: A total of 499 estrogen receptor-positive primary breast tumor specimens of advanced diseasepatients treated with first-line tamoxifen were genotyped for CYP2C19*2 and *17 variant alleles, with primary end point time-to-treatment failure (TTF). Effects of CYP2C19, independent of treatment, were analyzed in 243 primary systematic untreated patients. RESULTS:CYP2C19*2 hetero- and homozygote patients combined showed significantly longer TTFs (hazard ratio [HR]: 0.72; 95% CI: 0.57-0.90; p = 0.004). In multivariate analysis, including CYP2D6*4 status, CYP2C19*2 remained independently associated with TTF (HR: 0.73; 95% CI: 0.58-0.91; p = 0.007). In untreated patients, the CYP2C19*17 allele was significantly associated with a longer disease-free interval (HR: 0.66; 95%CI: 0.46-0.95; p = 0.025). CONCLUSION:CYP2C19 genotyping is potentially important for tamoxifen therapy for advanced disease and for breast cancer prognosis.
Authors: Lieke Mitrov-Winkelmolen; Marie-Christine W van Buul-Gast; Dingeman J Swank; Hans W P M Overdiek; Ron H N van Schaik; Daan J Touw Journal: Obes Surg Date: 2016-09 Impact factor: 4.129
Authors: L Weng; D Ziliak; H K Im; E R Gamazon; S Philips; A T Nguyen; Z Desta; T C Skaar; D A Flockhart; R S Huang Journal: Ann Oncol Date: 2013-03-18 Impact factor: 32.976
Authors: Matthew P Goetz; Katrin Sangkuhl; Henk-Jan Guchelaar; Matthias Schwab; Michael Province; Michelle Whirl-Carrillo; W Fraser Symmans; Howard L McLeod; Mark J Ratain; Hitoshi Zembutsu; Andrea Gaedigk; Ron H van Schaik; James N Ingle; Kelly E Caudle; Teri E Klein Journal: Clin Pharmacol Ther Date: 2018-01-31 Impact factor: 6.875
Authors: Jodie N Painter; Dale R Nyholt; Lutz Krause; Zhen Z Zhao; Brett Chapman; Christine Zhang; Sarah Medland; Nicholas G Martin; Stephen Kennedy; Susan Treloar; Krina Zondervan; Grant W Montgomery Journal: Fertil Steril Date: 2014-05-03 Impact factor: 7.329
Authors: K Beelen; M Opdam; T M Severson; R H T Koornstra; A D Vincent; M Hauptmann; R H N van Schaik; E M J J Berns; J B Vermorken; P J van Diest; S C Linn Journal: Breast Cancer Res Treat Date: 2013-06-05 Impact factor: 4.872
Authors: Mercedes Zafra-Ceres; Tomas de Haro; Esther Farez-Vidal; Isabel Blancas; Fernando Bandres; Eduardo Martinez de Dueñas; Enrique Ochoa-Aranda; Jose A Gomez-Capilla; Carolina Gomez-Llorente Journal: Int J Med Sci Date: 2013-05-27 Impact factor: 3.738